Post by GCI Health

16,189 followers

Balancing human trust and algorithmic reach is a must for pharma companies, and it was a defining topic of discussion at #CannesLions2026 this year. At WPP's panel, โ€œ๐“๐ก๐ž ๐๐ž๐ฐ ๐ˆ๐ง๐Ÿ๐ฅ๐ฎ๐ž๐ง๐œ๐ž ๐„๐ช๐ฎ๐š๐ญ๐ข๐จ๐ง: ๐๐š๐ฅ๐š๐ง๐œ๐ข๐ง๐  ๐‡๐ฎ๐ฆ๐š๐ง ๐“๐ซ๐ฎ๐ฌ๐ญ & ๐€๐ฅ๐ ๐จ๐ซ๐ข๐ญ๐ก๐ฆ๐ข๐œ ๐‘๐ž๐š๐œ๐ก,โ€ GCI Healthโ€™s Joe Malunda joined Jason Xenopoulos, (VML), Julie Keenan (Johnson & Johnson) and Michelle Rodemers Marino (Reddit, Inc.) for a dynamic discussion on how to build and maintain credibility when algorithms increasingly shape discovery. As Joe shared during the session: "๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐ข๐ฌ ๐Ÿ๐ข๐ง๐š๐ฅ๐ฅ๐ฒ ๐ญ๐ก๐ž ๐ญ๐ข๐ฉ ๐จ๐Ÿ ๐ญ๐ก๐ž ๐ฌ๐ฉ๐ž๐š๐ซ ๐Ÿ๐จ๐ซ ๐š๐๐จ๐ฉ๐ญ๐ข๐จ๐ง ๐š๐ง๐ ๐ข๐ง๐ง๐จ๐ฏ๐š๐ญ๐ข๐จ๐งโ€”๐ฌ๐ž๐ญ๐ญ๐ข๐ง๐  ๐ญ๐ก๐ž ๐ฉ๐š๐œ๐ž ๐Ÿ๐จ๐ซ ๐จ๐ญ๐ก๐ž๐ซ ๐ข๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ข๐ž๐ฌ, ๐›๐ž๐œ๐š๐ฎ๐ฌ๐ž ๐ญ๐ก๐ž ๐œ๐จ๐ง๐ฌ๐ž๐ช๐ฎ๐ž๐ง๐œ๐ž๐ฌ ๐จ๐Ÿ ๐ ๐ž๐ญ๐ญ๐ข๐ง๐  ๐ข๐ญ ๐ฐ๐ซ๐จ๐ง๐  ๐š๐ซ๐ž ๐ฉ๐ซ๐จ๐Ÿ๐จ๐ฎ๐ง๐.โ€

Post content